HomeAI · summaries
Storia in 3 fonti
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback - Tenax Therapeutics (NASDAQ:TENX)
Tenax Therapeutics announced Phase 3 LEVEL trial results for TNX-103, missing primary endpoints while showing subgroup benefits.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Heart failure drug from Tenax Therapeutics fails in pivotal study
A Tenax Therapeutics drug designed to treat a type of heart failure associated with high blood pressure in the lungs failed in a closely watched study.
- ·
benzinga.com
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback - Tenax Therapeutics (NASDAQ:TENX)
Tenax Therapeutics announced Phase 3 LEVEL trial results for TNX-103, missing primary endpoints while showing subgroup benefits.
